Cancer drug and uses

1. A pharmaceutical kit comprising an anti-diabetic drug, a statin, and a glycolysis inhibitor.

2. The pharmaceutical kit according to claim 1 , wherein the anti-diabetic drug is a biguanide, a thiazolidinedione, a secretagogue, an alpha-glucosidase inhibitor and/or a peptide analog, a cinnamon, a thiamine, or any combination thereof.

3. The pharmaceutical kit according to claim 2 , wherein the biguanide is a metformin, a phenformin, a buformin, or any combination thereof.

4. The pharmaceutical kit according to claim 1 , wherein the statin is an atorvastatin, a fluvastin, a lovastatin, a pitavastatin, a pravastatin, a rosuvastatin, a simvastatin, or any combination thereof.

5. The pharmaceutical kit according to claim 1 , wherein the glycolysis inhibitor is a hexokinase inhibitor, a phosphoglucose isomerase inhibitor, a fructosebisphosphate inhibitor, a triosephosphate isomerase inhibitor, a glyceraldehyde phosphate dehydrogenase inhibitor, a phosphoglycerate kinase inhibitor, a phosphoglycerate mutase inhibitor, an enolase inhibitor and/or a pyruvate kinase inhibitor, an anti-helminthic agent, an anti-malarial agent, an antibiotic, or any combination thereof.

6. The pharmaceutical kit according to claim 5 , comprising an anti-diabetic drug, a statin, an anti-helminthic agent, and an anti-malarial agent.

7. The pharmaceutical kit according to claim 6 , wherein the anti-diabetic drug is a biguanide, the anti-helminthic agent is a benzimidazole, and the anti-malarial agent is a doxycycline.

8. The pharmaceutical kit according to claim 7 , wherein the biguanide is a metformin, the statin is an atorvastatin, and the benzimidazole is a mebendazole.

9. The pharmaceutical kit according to claim 5 , wherein the anti-helminthic agent includes an abamectin, an aminoacetonitriles, a benzimidazole, a diethylcarbamazine, an ivermectin, a levamisole, niclosamide, an octadepsipeptides, a phosphoric acid, a praziquantel, a spiroindoles, a suramin, a pyrantel pamoate, or any combination thereof.

10. The pharmaceutical kit according to claim 9 , wherein the benzimidazole is an albendazole, a fenbendazole, a flubendazole, a thiabendazole, a triclabendazole, or any combination thereof.

11. The pharmaceutical kit according to claim 10 , wherein the flubendazole is a mebendazole.

12. The pharmaceutical kit according to claim 5 , wherein the anti-malarial agent includes an amodiaquine, an artemisinin, an atovaquone, a chloroquine, a clindamycin, a doxycycline, a halofantrine, a mefloquine, a primaquine, a proguanil, a pyrimethamine, a quinine, a rufigallol, a sulphonamide, or any combination thereof.

13. The pharmaceutical kit according to claim 12 , wherein the artemisinin is an arteether, an artelinate, an artelinic acid, an artemether, an artemotil, an artemisinin, an artenimol, an arterolane, an artesunate, a dihydroartemisinin, a dihydroartemisinin methyl ether, or any combination thereof.

14. The pharmaceutical kit according to claim 1 , further comprising a glucose intake inhibitor.

15. The pharmaceutical kit according to claim 14 , wherein the glucose intake inhibitor includes a GLUT-1 receptor inhibitor.

16. The pharmaceutical kit according to claim 15 , wherein the GLUT-1 receptor inhibitor is Vitamin C.

17. The pharmaceutical kit according to claim 1 , further comprising a lipid intake inhibitor.

18. The pharmaceutical kit according to claim 17 , wherein the lipid intake inhibitor includes an LDL receptor inhibitor, an SR-81 inhibitor, an SR-82 inhibitor, a SR-83/CD36 receptor inhibitor, or any combination thereof.

19. The pharmaceutical kit according to claim 18 , wherein the LDL receptor inhibitor is Vitamin D.

20. The pharmaceutical kit comprising a biguanide, a statin, a benzimidazole, and a cytotoxic antibiotic.

21. The pharmaceutical kit comprising a metformin, an atorvastatin, a mebendazole, and a doxycycline.